VERACYTE, INC. (VCYT) Form 8-K — Sep 14, 2026
Veracyte completed its acquisition of Convergent Genomics on September 14, 2026, under a merger agreement entered into on September 10, 2026. Convergent survived the merger as a wholly owned Veracyte subsidiary after Veracyte's Compass Merger Sub merged into it. Veracyte paid Convergent securityholders $150 million in aggregate cash consideration, subject to customary adjustments for cash, indebtedness, transaction expenses and net working capital. Veracyte may pay up to an additional $30 million in cash tied to milestones for UroAmp publications and reimbursement efforts.
Key figures
- Deal Value Usd
- 150000000
- Indemnity escrow amount
- $15,000,000
- Adjustment escrow amount
- $1,000,000
- Net working capital target
- $457,848
- Milestone payments potential
- $30 million (tied to UroAmp publication and reimbursement milestones)
- Representative expense amount
- $200,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.